{
  "trial_id": "NCT02485262",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Adult Chronic HCV patients aged >18",
      "label": "met",
      "evidence": "none"
    },
    {
      "criterion": "Treatment na\u00efve",
      "label": "met",
      "evidence": "none"
    },
    {
      "criterion": "Patient with cirrhosis and no cirrhosis. Cirrhosis defined as stage 4 fibrosis on liver biopsy or Fibro sure results indicating cirrhosis or has clinical findings suggestive of cirrhosis",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patients meet the indication to receive one of the SOF treatment based regimens",
      "label": "met",
      "evidence": "none"
    }
  ],
  "exclusion": [
    {
      "criterion": "Co-infected patients with HIV or Hepatitis B",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Patient received one of the DAAs regimens",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patient with active substance abuse and alcohol abuse",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Patient received prior DAA regimen",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Decompensated cirrhotic patients",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Patient has contraindication to receive SOF",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "Chronic HCV infection for the past 2 years. On IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months.",
  "_meta": {
    "topic_id": "27",
    "trial_id": "NCT02485262",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}